Cardio Diagnostics (CDIO) vs Anbio Biotechnology (NNNN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Anbio Biotechnology is the larger company by market cap ($145.7 million vs $4.7 million), about 30.8 times the size. Anbio Biotechnology converts more of its revenue into profit, with a net margin of 74.1% versus -43832.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CDIO | NNNN |
|---|---|---|
| Share price | $1.60 | $3.32 |
| Market cap | $4.74M | $145.72M |
| 1-day change | -3.03% | -9.04% |
| YTD return | — | -88.96% |
| 1-year return | — | -86.02% |
| P/E ratio (TTM) | — | 22.13 |
| EPS (TTM) | $-2.52 | $0.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $14.82K | $8.65M |
| Revenue growth (YoY) | -57.51% | +5.64% |
| Net income (latest FY) | $-6.50M | $6.40M |
| Gross margin | — | 87.24% |
| Operating margin | -43737.46% | 66.70% |
| Net margin | -43832.49% | 74.06% |
| 52-week high | $7.91 | $44.73 |
| 52-week low | $0.97 | $3.09 |
| Distance from 52-week high | -79.77% | -92.58% |
| Average volume | 26.91K | 128.35K |
| Shares outstanding | 2.96M | 43.89M |
| Employees | 15 | 27 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Anbio Biotechnology is about 30.8 times larger than Cardio Diagnostics by market value ($145.72M vs $4.74M).
- Anbio Biotechnology is more profitable, keeping 74.1 cents of every revenue dollar as net income versus -43832.5 cents for Cardio Diagnostics.
- Anbio Biotechnology grew revenue faster in its latest fiscal year (+5.64% vs -57.51%).
About Cardio Diagnostics
CDIO stock →Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 15 employees
About Anbio Biotechnology
NNNN stock →Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 27 employees
CDIO vs NNNN FAQ
Which is bigger, Cardio Diagnostics or Anbio Biotechnology?
Anbio Biotechnology (NNNN) is larger, with a market capitalization of $145.72M compared with $4.74M for Cardio Diagnostics (CDIO).
Are Cardio Diagnostics and Anbio Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.